Physician profile
Julia Flores
NPI 1699160440
$1,423.04
in general payments reported to CMS, 2019-2025
20 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.21 · 2020: $55.70 · 2021: $153 · 2022: $120 · 2023: $542 · 2024: $201 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.91 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $439.48 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $195.06 | 2022-2025 | Veozah |
| Lilly USA, LLC | $149.09 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $123.37 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $95.18 | 2019-2023 | |
| Amgen INC. | $59.95 | 2021-2023 | Repatha, Otezla |
| Dexcom, INC. | $39.91 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $38.54 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.29 | 2025 | |
| Shield Therapeutics INC | $36.16 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $30.13 | 2021 | |
| Sumitomo Pharma America, INC. | $26.42 | 2024 | Gemtesa |
| Biotronik Nro, INC. | $22.75 | 2025 | Prospera |
| Glaxosmithkline, LLC. | $22.00 | 2023 | Shingrix |
| Optinose US, INC. | $21.77 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.61 | 2023 | Quviviq |
| Abbvie INC. | $18.38 | 2024 | |
| Axsome Therapeutics, INC. | $18.06 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $16.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.29 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.